GILD’s (second) Selonsertib phase-3 failure in NASH—this time in F3-fibrosis patients: https://finance.yahoo.com/news/gileads-nash-drug-fails-meet-124021920.html https://finance.yahoo.com/news/gilead-announces-topline-data-phase-120000952.html